Neurotrope has formed its Alzheimer's Disease Clinical Advisory Board (CAB) with the following appointments: Jeffery L. Cummings, M.D., ScD, CCF; Martin R. Farlow, M.D.; Sam Gandy, M.D., Ph.D.; Christina Sampaio, M.D., Ph.D.; and Michael Weiner, M.D.

Charles S. Ramat, president and CEO of Neurotrope, said, "With our company having recently completed dosing patients in our phase IIa bryostatin study for the treatment of Alzheimer's disease, the appointment of our CAB members comes at a pivotal time for Neurotrope. We look forward to the release of data from that study early in 2015 and the assistance from our new CAB members in helping us further the clinical development and eventual commercialization of this important potential treatment for Alzheimer's disease."

Cummings, chairman, is director of Cleveland Clinic Lou Ruvo Center for Brain Health; director of Materials Science and Engineering Center for Alzheimer's Disease Research; and director of the Deane F. Johnson Center for Neurotherapeutics at UCLA.

Farlow is professor and vice chairman of research, dept. of neurology, at Indiana University; associate co-director of the Indiana Alzheimer's Disease Center; and member of the government Alzheimer's task force.

Gandy works at Mount Sinai. Gandy is chair in Alzheimer's research and is a professor of neurology and psychiatry at Mount Sinai. Gandy was director of the Mount Sinai Center for Cognitive Health and NFL Neurological Care, is a former chairman of the National Medical and Scientific Advisory Council of the Alzheimer's Association and is founding director of the Farber Institute of Neurosciences, Jefferson Medical College.

Sampaio is chief medical officer at the Cure Huntington's Disease Initiative Foundation; professor of clinical pharmacology and therapeutics at the University of Lisbon, Portugal; and former member of the Committee of Proprietary Medicinal Products and the Scientific Advice Working Party at the EMA.

Weiner is a professor at UCSF School of Medicine in radiology and biomedical imaging and Principal Investigator of the Alzheimer's Disease Neuroimaging Initiative